Freshfields has advised Permira and Nordic Capital on their all-cash, voluntary, and recommended public takeover offer for Bavarian Nordic.
Bavarian Nordic is a vaccine company headquartered in Denmark.
According to Freshfields, the offer, made via Innosera ApS, values Bavarian Nordic’s equity at approximately USD 2.98 billion. The transaction will see Permira and Nordic Capital acquire all issued and outstanding shares in Bavarian Nordic, which is known for its mpox and smallpox vaccine portfolio, as well as for supplying travel vaccines and contributing to global health preparedness efforts.
The Freshfields team included Vienna-based Counsel Lukas Pomaroli and Associate Marcel Neuhauser, as well as further lawyers in Frankfurt, Hamburg, Munich, and London.
Freshfields did not respond to our inquiry on the matter.
